156 related articles for article (PubMed ID: 35293552)
1. Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer.
Kneubil MC; Goulart KOB; Brollo J; Coelho GP; Mandelli J; Orlandin BC; Corso LL; Roesch-Ely M; Henriques JAP
Braz J Med Biol Res; 2022; 55():e11857. PubMed ID: 35293552
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
3. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
Zuo K; Yuan X; Liang X; Sun X; Liu S; Connell PP; Li X; Yang W
Breast Cancer Res Treat; 2022 Jan; 191(2):335-344. PubMed ID: 34797456
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of DNA repair gene in breast cancer metastasis.
Yang Y; Li X; Hao L; Jiang D; Wu B; He T; Tang Y
Sci Rep; 2020 Nov; 10(1):19626. PubMed ID: 33184404
[TBL] [Abstract][Full Text] [Related]
5. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
6. Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in
Sokolenko AP; Moiseyenko FV; Iyevleva AG; Ivantsov AO; Dolmatov GD; Shelekhova KV; Gulo EV; Topal AX; Artemieva EV; Abduloeva NH; Rysev NA; Barsova DA; Levchenko NV; Volkov NM; Egorenkov VV; Moiseyenko VM; Imyanitov EN
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768191
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Gianni L; Zambetti M; Clark K; Baker J; Cronin M; Wu J; Mariani G; Rodriguez J; Carcangiu M; Watson D; Valagussa P; Rouzier R; Symmans WF; Ross JS; Hortobagyi GN; Pusztai L; Shak S
J Clin Oncol; 2005 Oct; 23(29):7265-77. PubMed ID: 16145055
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
Watanabe Y; Maeda I; Oikawa R; Wu W; Tsuchiya K; Miyoshi Y; Itoh F; Tsugawa K; Ohta T
Genes Cells; 2013 Dec; 18(12):1120-30. PubMed ID: 24581343
[TBL] [Abstract][Full Text] [Related]
9. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
10. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
Singh LC; Chakraborty A; Mishra AK; Devi TR; Sugandhi N; Chintamani C; Bhatnagar D; Kapur S; Saxena S
Med Oncol; 2012 Jun; 29(2):539-46. PubMed ID: 21528410
[TBL] [Abstract][Full Text] [Related]
11. ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy.
Veys I; Pop CF; Barbieux R; Moreau M; Noterman D; De Neubourg F; Nogaret JM; Liberale G; Larsimont D; Bourgeois P
PLoS One; 2018; 13(5):e0197857. PubMed ID: 29799849
[TBL] [Abstract][Full Text] [Related]
12. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Sci; 2018 Jan; 109(1):166-173. PubMed ID: 29047188
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
15. EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.
Buechler SA; Gökmen-Polar Y; Badve SS
Breast; 2019 Feb; 43():74-80. PubMed ID: 30502641
[TBL] [Abstract][Full Text] [Related]
16. Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
Dasgupta H; Islam S; Alam N; Roy A; Roychoudhury S; Panda CK
J Surg Oncol; 2019 Jan; 119(1):88-100. PubMed ID: 30481381
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
[TBL] [Abstract][Full Text] [Related]
18. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
19. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
[TBL] [Abstract][Full Text] [Related]
20. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]